All Trials

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1) who are ARSI- and abiraterone-naïve (prior docetaxel for mCSPC allowed if no early progression) are randomized to enzalutamide plus the EZH2 inhibitor mevrometostat (PF-06821497) vs enzalutamide alone. The investigational agent targets EZH2/PRC2 to reduce H3K27 methylation and potentially enhance antitumor activity; primary endpoint is rPFS.

ClinicalTrials.gov ID: NCT06629779

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-sensitive prostate adenocarcinoma (ECOG 0–1) are randomized to physician’s choice of abiraterone, enzalutamide, or darolutamide plus the PARP1-selective inhibitor saruparib (AZD5305) versus placebo, with parallel cohorts for HRR-mutated and non-HRR–mutated disease. Saruparib selectively inhibits and traps PARP1 to exploit HRR deficiency, aiming to improve radiographic PFS while potentially reducing hematologic toxicity seen with nonselective PARP inhibitors.

ClinicalTrials.gov ID: NCT06120491

PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PSMA-positive mCRPC who have progressed after ARPI, taxane chemotherapy, and [177Lu]Lu‑PSMA are randomized to the alpha-emitting PSMA radioligand AAA817 (225Ac‑PSMA‑617) versus investigator’s choice of standard of care. AAA817 targets PSMA to deliver actinium‑225 alpha radiation to tumor cells; xerostomia is a known risk, with monitoring for hematologic and renal toxicity.

ClinicalTrials.gov ID: NCT06780670

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: ARPI‑naïve men with metastatic castration‑resistant or hormone‑sensitive prostate cancer (plus a Japanese safety cohort) receive long‑acting intramuscular abiraterone decanoate (ASP5541), a CYP17A1 inhibitor prodrug dosed about every 12 weeks, with or without prednisone/prednisolone, compared against standard daily oral abiraterone acetate with corticosteroid. Key comparisons include PSA responses in mCRPC and activity/safety (including mineralocorticoid toxicity) in mHSPC.

ClinicalTrials.gov ID: NCT07005154

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: PSMA‑positive mCRPC after progression on ≥12 weeks of an ARPI, ECOG 0–2, and adequate organ function; excludes prior PSMA‑targeted therapy, recent radioisotopes, PARP inhibitors, and chemotherapy for mCRPC (docetaxel in mCSPC allowed). Randomizes to 177Lu‑TLX591 (rosopatamab tetraxetan), a PSMA‑targeted beta‑emitting radioimmunotherapy, plus SOC (enzalutamide, abiraterone/prednisone, or docetaxel/prednisone) versus SOC alone.

ClinicalTrials.gov ID: NCT06520345

PRO-XL: A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 (177Lu)-PSMA-617

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with radiographic mCRPC who have progressed after 177Lu‑PSMA‑617 receive oral zanzalintinib (XL092) monotherapy once daily. XL092 is an investigational multikinase TKI targeting VEGFR2, MET, and TAM kinases (TYRO3/AXL/MER) to inhibit angiogenesis and tumor growth; primary endpoint is 16‑week disease control.

ClinicalTrials.gov ID: NCT06568562

A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer, the SYNERGY-201 Trial

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with mCRPC who have progressed on abiraterone (without prior enzalutamide/apalutamide/darolutamide or recent radionuclide therapy) receive enzalutamide plus SX-682, an oral CXCR1/2 inhibitor that blocks MDSC trafficking to modulate the tumor microenvironment. Key exclusions include liver metastases, significant CV disease, active autoimmune/infectious disease, and use of strong CYP3A4 modulators or QT‑prolonging drugs.

ClinicalTrials.gov ID: NCT06228053

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adult men with high‑volume metastatic hormone‑sensitive prostate adenocarcinoma (ECOG 0–2, castrate testosterone) are randomized to luxdegalutamide (JSB462), an oral PROTAC androgen receptor degrader, plus abiraterone (two dose levels) versus standard ARPI therapy (abiraterone or enzalutamide). Prior second‑generation ARPI for advanced/metastatic disease is excluded; limited prior (neo)adjuvant therapy allowed if completed >12 months before randomization.

ClinicalTrials.gov ID: NCT06991556

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with well-differentiated (Grade 1–3) unresectable or metastatic pancreatic or extra-pancreatic NETs with recent RECIST-defined progression and no prior VEGFR TKI or mTOR inhibitor are randomized to zanzalintinib (XL092, an oral multi-kinase inhibitor of VEGFR2/MET/TAM) versus everolimus. Excludes NECs and select NET subtypes; primary endpoint is PFS by blinded central review.

ClinicalTrials.gov ID: NCT06943755

A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic, microsatellite-stable pancreatic ductal adenocarcinoma that has progressed on at least one prior systemic therapy receive SBRT to selected lesion(s) followed by dual checkpoint blockade with botensilimab (Fc‑enhanced anti–CTLA‑4) plus balstilimab (anti–PD‑1). Eligible patients require ECOG 0–1, measurable disease, adequate organ function, ≤25% liver tumor burden, and no active CNS metastases or significant autoimmune/immunosuppression.

ClinicalTrials.gov ID: NCT06843551